Evidence map›Paper›PMID 40500566›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

Comprehensive multi-omics analysis of bile acid metabolism in hepatocellular carcinoma: implications for prognosis, immune microenvironment, and therapeutic resistance.

Jiayan Ma, Ming Cheng, Limin Jin, Yong Wang, Zhengyang Feng, Yuntian Shen, Yaqun Zhu, Qiliang Peng

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiayan Ma *Department of Experimental Center, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Ming Cheng *Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Limin Jin *Department of Radiotherapy & Oncology, The Second Affiliated Hospital of Soochow University, San Xiang Road No. 1055, Suzhou, 215004, Jiangsu, China.
Yong WangDepartment of Radiotherapy & Oncology, The Second Affiliated Hospital of Soochow University, San Xiang Road No. 1055, Suzhou, 215004, Jiangsu, China.
Zhengyang FengDepartment of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Yuntian ShenDepartment of Radiotherapy & Oncology, The Second Affiliated Hospital of Soochow University, San Xiang Road No. 1055, Suzhou, 215004, Jiangsu, China.
Yaqun ZhuDepartment of Radiotherapy & Oncology, The Second Affiliated Hospital of Soochow University, San Xiang Road No. 1055, Suzhou, 215004, Jiangsu, China.
Qiliang PengDepartment of Radiotherapy & Oncology, The Second Affiliated Hospital of Soochow University, San Xiang Road No. 1055, Suzhou, 215004, Jiangsu, China. pengqiliang1912@163.com.ORCID http://orcid.org/0000-0002-0248-8826

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with metabolic reprogramming playing a critical role in its progression. Bile acid metabolism has emerged as a key pathway in hepatocarcinogenesis, yet its comprehensive role in HCC remains poorly understood. This study aims to systematically investigate the dysregulation of bile acid metabolism in HCC and its clinical implications.

methodsWe performed gene set enrichment analysis (GSEA), genomic alteration analysis, transcriptional profiling, and DNA methylation analysis using transcriptomic and genomic data from the TCGA cohort. A bile acid metabolism signature was developed using single-sample GSEA (ssGSEA), and its prognostic value was assessed through Kaplan-Meier survival and Cox regression analyses. Immune cell infiltration and associations with immunotherapy and chemotherapy response were also evaluated.

resultsUsing training data from 368 HCC patients and validation cohorts (n = 221), significant dysregulation of bile acid metabolism was observed, with distinct pathway activation across clinical subgroups (P < 0.05). Genomic alterations, including mutations and copy number variations, were identified in key bile acid metabolism-related genes. The bile acid metabolism signature was strongly associated with overall survival and tumor stage (P < 0.05). Immune cell infiltration patterns varied significantly between high and low bile acid metabolism groups, suggesting a role in shaping the tumor immune microenvironment. However, no significant association was found between the signature and immunotherapy response.

conclusionThis study highlights the critical role of bile acid metabolism in HCC progression, with potential implications for prognosis and therapeutic targeting. The bile acid metabolism signature serves as a robust prognostic indicator, offering insights into personalized treatment strategies.

Indexed as

Bile Acids and SaltsCarcinoma, HepatocellularDrug Resistance, NeoplasmLiver NeoplasmsTumor MicroenvironmentAgedDNA Copy Number VariationsDNA MethylationFemaleGene Expression ProfilingHumansImmunotherapyMaleMiddle AgedMultiomicsPrognosisBile Acids and SaltsBile acid metabolismHepatocellular carcinomaMetabolic reprogrammingPrognostic signatureTumor microenvironment

Identifiers

PMID40500566

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.